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ABSTRACT 
We here describe the preparation of a series of hybrid molecules containing a combretastatin A-4 
moiety and a pironetin analogue fragment. The cytotoxic activities of these compounds have been 
measured. Relations between structure and cytotoxicity are discussed. Some of the tested compounds 
showed cytotoxicity values of the same order of magnitude as the parental molecules, combretastatin A-
4 and pironetin, and were less toxic than the latter for normal cells. 
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HIGHLIGHTS 
 Hybrid molecules containing a combretastatin A-4 moiety and a pironetin analogue 
fragment have been prepared and tested for cytotoxicity against a normal and two tumoral 
cell lines. 
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 Some of the tested compounds show cytotoxicity values of the same order of magnitude as 
the parental molecules, combretastatin A-4 and pironetin. 
 The normal vs. tumoral cytotoxicity ratio of some of the tested compounds are higher than 
in the case of the parental molecules, that is, they are safer than the latter compounds. 
 
1. Introduction 
It is widely known that cancer, one leading cause of death in developed countries [1], may be 
induced by a plethora of both external and internal factors, including genetic mutations. Accordingly, a 
number of types of therapeutic attack has been investigated [2,3]. One of these involves the use of 
cytotoxic drugs, which exert their effect in many cases by means of inducing various mechanisms of 
cell death [4]. Many of such drugs owe this property to interaction with the microtubule network. 
Microtubules are dynamic polymers that play a central role in a number of cellular processes, most 
particularly cell division, as they are key constituents of the mitotic spindle. Microtubules are 
constituted of a protein named tubulin, the functional form of which is a heterodimer formed through 
non-covalent binding of two monomeric constituents, called - and -tubulin. For cell division to occur 
in a normal way, microtubules must be in a constant state of formation and disruption, a process named 
microtubule instability 5. Any molecule which influences microtubule instability will also influence 
the cell division process, not only of normal cells but also of tumoral ones. Therefore, it is not surprising 
that tubulin-binding molecules (TBM) constitute a most important class of anticancer agents. TBMs 
may be divided in two broad categories, those that bind to -tubulin and those that bind to -tubulin. 
The latter group is presently by far the most numerous and contains products which cause either 
disruption or stabilization of microtubules. Among the drugs that belong to this group, colchicine 6 
and the combretastatins 7 (Fig. 1) exert their effects by causing disruption of microtubules. In contrast, 
another important representative of the same group, paclitaxel, was the first-described tubulin-binding 
drug that was found to stabilize microtubules 8. Even though they display opposite effects, these drugs 
are known to bind to -tubulin, whenever to different sites within this protein subunit 9-11. 
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Figure 1. Structures of some natural products reported to selectively bind to -tubulin. 
The number of products that bind to -tubulin is very small, the naturally occurring 5,6-dihydro--
pyrone pironetin being the first-reported example 12, followed a short time later by the peptide-like 
hemiasterlin family 13 (Fig. 2). Pironetin is a potent inhibitor of tubulin assembly and has been found 
to arrest cell cycle progression in the G2/M phase 14. 
 
Figure 2. Structure of two natural products reported to selectively bind to -tubulin. 
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Some structure-activity (SAR) studies on pironetin have been reported. These studies have shown 
that the presence of the conjugated C2C3 double bond and of the hydroxyl group at C-9, either free or 
methylated, are essential for the biological activity. The presence of a (7R)-hydroxyl group also seems 
to be relevant. It has been suggested that the Lys352 residue of the -tubulin chain adds in a Michael 
fashion to the conjugated double bond of pironetin, therefore forming a covalent bond with C-3 of the 
dihydropyrone ring (Fig. 3). In addition, it has been suggested that the Asn258 residue of -tubulin 
holds the pironetin molecule through two hydrogen bonds to the dihydropyrone carbonyl and the 
methoxyl oxygen atoms 14. 
 
Figure 3. Schematic model of the covalent union of pironetin to its binding site at the -tubulin surface. 
 
The emergence of resistances to existing drugs has led to a continuous need of developing new 
bioactive compounds that overcome such problems. Even though first observed in the case of antibiotics 
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[15], resistances have been reported to therapies with various types of cytotoxic agents [16]. The 
investigation of new compounds with such biological properties therefore constitutes an important goal 
in chemistry and pharmacology. 
 
2. Concept and design of hybrid tubulin-binding ligands 
As a member of the up to now small group of TBMs that bind to -tubulin, pironetin constitutes a 
pharmacologically interesting target. Not surprisingly, an appreciable number of total syntheses of this 
natural compound has appeared in the literature [17]. In order to develop SAR studies based upon the 
pironetin framework, we designed two years ago [5a] a simplified model structure where all elements 
that had not yet proven to be essential for the biological activity were removed. The target structures I/II 
are schematically shown in Figure 4. The elements that were maintained are the conjugated 
dihydropyrone ring and the side chain with the methoxy group at C-9. The hydroxyl group at C-7 was 
removed in some substrates (I) and retained in others (II), in order to see its influence on the activity. 
All alkyl pendants (methyl groups at C-8 and C-10, ethyl at C-4) and the isolated C12−C13 double bond 
were removed. The configurations of the two/three remaining stereocentres were then varied in a 
systematic way. Thus, all four possible stereoisomers with general constitution I, with no hydroxyl 
group at C-7, were prepared. Likewise, all eight stereoisomers exhibiting general structure II, with a 
hydroxyl group at C-7, were synthesized [5a]. 
 
Figure 4. General structures of simplified pironetin analogues of the first generation (ref. 5a). 
 
The cytotoxic activity of these analogues and their interactions with tubulin were subsequently 
investigated. It was found on one hand that analogues I/II were cytotoxic in the low micromolar range, 
about three orders of magnitude less active than the parent molecule. On the other hand, we also found 
that they behave in the same way as pironetin, share the mechanism of action of the natural compound 
and compete for the same binding site in -tubulin. As the parent compound, they also lead to 
disruption of the microtubule network [5a]. 
With the aim at extending our project, our idea was to prepare cytotoxic TBMs with a dual ability to 
bind to both - and -tubulin and exert a microtubule-destabilizing effect. Since these properties are 
specifically exhibited by pironetin (binds to -tubulin) and combretastatin A-4 (binds to -tubulin), 
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respectively, we decided to prepare hybrid molecules such as 1-8 (Fig. 5) containing a moiety of 
combretastatin A-4 (itself numbered as 13 in Fig. 5) and another of the simplified pironetin type (14, 
ent-14 and 15), connected in turn by an ester spacer of variable length. Some of them have been 
prepared in both antipodal forms (1 to 4 and ent-1 to ent-4) [18]. 
 
Figure 5. Structures of the pironetin analogue/combretastatin A-4 hybrids used in this study (1-8) and of 
their synthetic precursors (9-15), including combretastatin A-4 (13). 
3. Synthetic work 
Combretastatin A-4 (13) was prepared according to a literature procedure 19. Its O-alkyl 
derivatives 9a-12a were prepared by means of O-alkylation with commercially available -bromoesters 
16-19 (Scheme 1). Saponification of esters 9a-12a gave the corresponding acids 9b-12b. 
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Scheme 1. Synthesis of combretastatin A-4 derivatives 9a-12a and 9b-12b: (a) K2CO3, DMF, RT, 24 h 
(9a, 91%; 10a, 91%; 11a, 98%; 12a, 90%); (b) aq NaOH, MeOH, RT, 18 h (9b, 90%; 10b, 78%; 11b, 
72%; 12b, 75%). Acronyms and abbreviations: DMF, N,N-dimethylformamide. 
 
The synthesis of the pironetin fragments 14, ent-14 and 15 depicted in Scheme 2, was performed 
according to the general concept used in our previous papers [5a,b]. Thus, Brown´s asymmetric 
allylation 20 of the known aldehyde 16 21 afforded homoallyl alcohol 17. The required chiral 
allylborane was prepared through reaction of allylmagnesium bromide with the commercially available 
(−)-diisopinocampheylboron chloride, (−)-Ipc2BCl. Reaction of 17 with acryloyl chloride at low 
temperature gave acrylate 18, which was subjected to ring-closing metathesis (RCM) 22 in the 
presence of Grubbs first-generation catalyst Ru-I. This furnished dihydropyrone 19, deprotection of 
which provided 14 in good yield. Dihydropyrone ent-14 was prepared in the same way except that (+)-
Ipc2BCl was the chiral boron reagent used. 
Dihydropyrone 15 was not connected as such with the combretastatin A-4 fragment but as its O-silyl 
derivative 28 (Scheme 2), which was also prepared according to the previous methodology. Brown´s 
asymmetric allylation of the known aldehyde 20 23 furnished alcohol 21, which was then converted 
into methyl ether 22. The latter was then sequentially subjected to a two-step oxidative cleavage of the 
olefinic bond, followed by Brown´s asymmetric allylation to yield 23. Silylation of the hydroxyl group 
of 23 and repetition of the previous sequence gave alcohol 25, which was esterified with acryloyl 
chloride. The resulting acrylate 26 was subjected to ring-closing metathesis to 27, which was then 
oxidatively deprotected [24] to 28. Desilylation of 28 gave 15, which was used in the biological 
evaluations. 
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Scheme 2. Synthesis of pironetin fragments 14, ent-14 and 15. (a) (−)-Ipc2BCl, allylMgBr, Et2O, 78 
ºC, 1 h, then addition of the aldehyde, 1 h, 78 ºC (17: 76%, e.r. 96:4; 21: 90%, e.r. 94:6; 25, 70% 
overall yield from 24, d.r. 76:24); (b) CH2=CHCOCl, CH2Cl2, iPr2NEt, 78 ºC, 30 min (18: 94%; ent-
18: 90%; 26, 98%); (c) 10% cat. Ru-I, CH2Cl2, , 2 h (19: 81%; ent-19: 80%; 27: 83%); (d) DDQ, wet 
CH2Cl2, 30 min. (14: 69%; ent-14: 67%; 28: 84%); (e) (+)-Ipc2BCl, allylMgBr, Et2O, 78 ºC, 1 h, then 
addition of the aldehyde, 1 h, 78 ºC (ent-17: 89%, e.r. 96:4; 23: 90% overall yield from 22, d.r. 86:14); 
(f) NaH, THF, 0 ºC, then MeI, RT, overnight (88%); (g) 1) OsO4, NMO, aq tBuOH, THF, RT, 
overnight. 2) Pb(OAc)4, CH2Cl2, 0ºC; (h) TBSOTf, 2,6-lut, 0 ºC, 1 h (80%); i) PPTS (cat.), MeOH, , 
overnight (85%). Acronyms and abbreviations: Ipc, isopinocampheyl; DDQ, 2,3-dichloro-5,6-dicyano-
p-benzoquinone; TBS, tert-butyldimethylsilyl; NMO, N-methylmorpholine N-oxide; 2,6-lut, 2,6-
lutidine; PPTS, pyridinium p-toluenesulfonate. 
 
Dihydropyrones 1-8, including ent-1 to ent-4, were prepared by esterification of acids 9b-12b with 
dihydropyrones 14, ent-14 and 28 by means of the Yamaguchi method [25] (Scheme 3). In the case of 
compounds 5-8, an additional desilylation step was required. 
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Scheme 3. Synthesis of hybrid molecules 1-4, ent-1 to ent-4, 5-8. (a) 9b-12b, 2,4,6-trichlorobenzoyl 
chloride, Et3N, RT, then addition of the alcohol component, RT, 2 h (1: 34%; 2: 47%; 3: 37%; 4: 35%; 
ent-1: 42%; ent-2: 55%; ent-3: 37%; ent-4: 49%; 29: 25%; 30: 40%; 31: 44%; 32: 21%); (b) PPTS 
(cat.), MeOH, , overnight (5: 85%; 6: 95%; 7: 80%; 8: 85%). 
 
After the synthesis of the pironetin-combretastatin A-4 hybrids was completed, the compounds were 
investigated in relation to their cytotoxic activity towards two types of tumoral lines and one normal cell 
line. 
 
4. Biological work 
4.1. Cellular effects of the compounds. Cytoxicity values. 
We carried out a measurement of the cytotoxicity of the synthetic combretastatin A-4 derivatives 1-4 
and their enantiomers, 5-8, 9a-12a and 9b-12b. Pironetin analogues 14, ent-14 and 15 were also tested. 
Cytotoxicity assays were performed as described in the Experimental Section using two tumoral cells, 
the human colon HT-29 and the breast adenocarcinoma MCF-7 cell lines, as well as one normal cell 
line, the human embryonic kidney cell line, HEK-293 [26]. Cytotoxicity values, expressed as the 
compound concentration (µmol/L) that causes 50% inhibition of cell growth (IC50), are shown in Table 
1. The observed values are in most cases in the low to medium micromolar range. Compounds ent-1, 3, 
7, 10a, 11a, 12a and 12b showed the highest cytotoxicities for the HT-29 cell line, with IC50 values 
which were not very different (in some cases even lower) of those of combretastatin A-4 and pironetin 
for this particular cell line. In the case of the MCF-7 cell lines, the lowest IC50 values were shown by 
compounds 7, 9b, 10a, 11a, 11b, 12a, 12b and 15. But a further aspect which is also worth mentioning 
is the fact that some of the synthetic compounds are much more toxic for tumoral cells than for normal 
ones, an obviously desirable feature. This can better appreciated with the  and   coefficients, obtained 
by dividing the IC50 values of the normal cell line (HEK-293) by those of one or the other tumoral cell 
line (see footnote in the Table). The higher value of either the  or the   coefficient, the higher the 
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therapeutic safety margin of the compound in the corresponding cell line. Thus, combretastatin A-4 
itself shows good values of both coefficients, most particularly in the case of the MCF-7 cell line. 
Pironetin shows a similarly good value for the HT-29 cell line (), but much less so for the MCF-7 cell 
line. Among the compounds which show a high cytotoxicity (low IC50 values), ent-1, 7, 11a, 12a and 
12b are particularly worth mentioning as they exhibit high both  and   values. Compounds 3 shows a 
good selectivity only in the case of the HT-29 line ( > 30) whereas compounds 11b and 15 show a 
good selectivity in the specific case of the MCF-7 line (  > 60). 
Some aspects related to the relation between the structures and the observed cytotoxicity deserve 
comment. In the case of two subsets of hybrid molecules [27] where there are differences between in the 
carbon chain length (e.g. 1-4 and 5-8), the cytotoxicity reaches a maximum for compounds having a ten-
carbon chain in the combretastatin A-4 segment (3, 7). The cytotoxicities of the compounds of the 
enantiomeric series (ent-1 to ent-4) are not too different from those of 1-4, even though the maximum 
cytotoxicity is found here for ent-1, the compound with the shorter carbon chain. It is difficult to 
propose now an explanation for this fact, as we do not yet know whether these compounds are 
interacting with tubulin at the pironetin site (-tubulin), at the combretastatin A-4 site (-tubulin) or at 
both sites simultaneously. Research in this direction is being currently performed. 
We have also tested the synthetic intermediates used for the preparation of the aforementioned hybrid 
molecules. As regards combretastatin A-4 derivatives 9-12a/b, a dependence of the cytotoxicity from 
the carbon chain length is also observed (Table 1). For the methyl esters (9a-12a), a marked increase in 
the cytotoxicity is observed in going from the compound with the three-carbon chain (9a) to those 
having longer chains (10a-12a), with the IC50 values of the three latter being very similar (with both 
tumoral cell lines) and comparable with those of combretastatin A-4 itself. As for the free acids (9b-
12b), the cytotoxicities vary in a rather erratic way and no relation is perceived between IC50 values and 
the chain length. Furthermore, marked differences also observed in some cases between the IC50 values 
for the two tumoral cell lines. 
The cytotoxicities of the three pironetin analogues 14, ent-14 and 15 were also measured. Compound 
14 and its enantiomer, which display a single stereocentre, represent the most simplified model possible 
for pironetin. From the results presented in Table 1, it is evident that 14 and ent-14 show a very low 
cytotoxicity, much below of that observed for the hybrid molecules (1 to 3, and ent-1 to ent-3) bearing 
these fragments (exceptions to this are 4 and ent-4, which show very high IC50 values, perhaps because 
of solubility problems). Even if conclusions must be still provisory, this seems to point to 1-3 and their 
enantiomers owing their cytotoxicity to interactions with tubulin through the combretastatin A-4 end. As 
regards compound 15, it has three stereocentres and corresponds more closely to the pironetin models 
we have being investigating in recent years [5]. Table 1 shows that its cytotoxicity for the two tumoral 
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cells is indeed much higher than those of 14/ent-14, most particularly in the case of the MCF-7 cell line. 
From the hybrid molecules 5-8 having this structural fragment, the highest cytotoxicity is shown by 7, 
the molecule that displays the ten-carbon chain, as commented above. It is also worth noting that the 
IC50 value of 7 with the HT-29 cell line is much lower than the IC50 values of both 11b and 15, its two 
precursor components. This suggests that a hydrolysis of 7 into 11b and 15 is not taking place within the 
cell. 
 
Table 1. Cytotoxicity of pironetin analogue/combretastatin A-4 hybrids 1-8 and ent-1 to ent-4, 
combretastatin A-4 derivatives 9a-12a and 9b-12b, and pyrones 14, ent-14 and 15.a 
Compound HT-29 MCF-7 HEK-293 b c 
CoA4 4.2 ± 0.5 1 ± 0.2 25 ± 3 5.9 25 
Pironetin 8 ± 2 18 ± 3 46 ± 6 5.7 2.5 
1 12 ± 2 52 ± 10 39 ± 4 3.2 0.7 
2 32 ± 5 > 300 80 ± 14 2.5 < 0.3 
3 10 ± 1 > 300 > 300 > 30 ‒ 
4 107 ± 5 > 300 > 300 > 2.8 ‒ 
ent-1 3.5 ± 0.9 17 ± 2 114 ± 5 32 6.7 
ent-2 19 ± 6 > 300 > 300 > 15 ‒ 
ent-3 38 ± 3 69 ± 7 59 ± 10 1.6 0.8 
ent-4 64 ± 7 > 300 72 ± 3 1.1 < 0.3 
5 15.4 ± 0.5 31 ± 1 22 ± 2 1.4 0.7 
6 44 ± 5 > 300 > 300 > 6.8 ‒ 
7 2.9 ± 0.2 5.6 ± 0.1 22 ± 2 7.6 3.9 
8 50.8 ± 0.6 21 ± 4 81 ± 10 1.6 3.8 
9a 60.1 ± 0.5 10.4 ± 0.5 121 ± 5 2 12 
9b 50 ± 2 2.9 ± 0.2 67 ± 2 1.4 23 
10a 3.5 ± 0.3 9.6 ± 0.2 9.6 ± 0.3 2.7 1 
10b 16 ± 2 17 ± 4 > 300 > 19 > 18 
11a 8 ± 1 3 ± 0.6 > 300 > 37 > 100 
11b 103 ± 6 5 ± 0.9 > 300 > 30 > 60 
12a 5 ± 1 9.6 ± 0.2 > 300 > 60 > 30 
12b 1.9 ± 0.3 4.4 ± 0.8 39 ± 5 20 8.8 
14 109 ± 20 > 300 206 ± 15 1.9 < 0.7 
ent-14 81 ± 12 109 ± 8 119 ± 16 1.5 1.1 
15 25.4 ± 0.2 2.5 ± 0.4 > 300 > 12 > 120 
 
aIC50 values, which include those of the parent compounds combretastatin A-4 (CoA4) and 
pironetin, are expressed as the compound concentration (µmol/L or M) that causes 50% 
inhibition of cell growth. The values are the average ( s.d.) of three different measurements 
performed as described in the Material and Methods section. b = IC50 (HEK-293) / IC50 (HT-29). 
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c = IC50 (HEK-293) / IC50 (MCF-7). Values of  and  have been rounded off to a decimal 
figure. Compounds with both high cytotoxicity towards one or the two tumoral cell lines and low 
cytotoxicity towards the normal cell line have been highlighted. 
 
5. Summary and conclusions 
We have prepared a set of synthetic hybrid molecules containing a combretastatin A-4 moiety and a 
fragment structurally related to the natural product pironetin. Some of these molecules have been 
synthesized in both enantiomeric forms. Their cytotoxic action (IC50 values) towards a normal (HEK-
293) and two tumoral (HT-29 and MCF-7) cell lines has then been measured. While most of the 
synthetic derivatives proved cytotoxic towards at least one of the two tumoral cell lines, some of them 
showed cytotoxic activities of the same order as the natural compounds pironetin and combretastatin A-
4. More interesting was the fact that, for some of the compounds, the normal vs. tumoral cytotoxicity 
ratio was markedly higher than in the case of the two aforementioned natural products, that is, they 
proved comparatively less cytotoxic towards normal cells (these compounds are highlighted in Table 1). 
This may possibly endow these compounds with pharmacological interest. 
 
 
6. Experimental 
6.1. Chemistry. General procedures 
The general reaction conditions and the physical and spectral data of all synthetic intermediates and 
final compounds are described in detail in the Supporting Information. The samples of compounds used 
for the biological studies were purified to > 95% by means of preparative HPLC. 
6.2. Biological studies. Materials and methods 
6.2.1. Reagents and cell culture 
Cell culture media were purchased from Gibco (Grand Island, NY, USA). Fetal bovine serum (FBS) 
was a product of Harlan-Seralab (Belton, U.K.). Supplements and other chemicals not listed in this 
section were obtained from Sigma Chemicals Co. (St. Louis, Mo., USA). Plastics for cell culture were 
supplied by Thermo ScientificTM BioLite. All tested compounds were dissolved in DMSO at a 
concentration of 10 g/mL and stored at –20C until use. 
Cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing glucose (1 
g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 µg/mL) and amphoterycin (1.25 
µg/mL), supplemented with 10% FBS. 
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6.2.2. Cytotoxicity assays 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Co., St. 
Louis, MO) dye reduction assay in 96-well microplates was used, as previously described [28]. Some 5 
x 103 cells of HT-29, MCF-7 or HEK-293 cells in a total volume of 100 µL of their respective growth 
media were incubated with serial dilutions of the tested compounds. After 3 days of incubation (37 C, 
5% CO2 in a humid atmosphere), 10 µl of MTT (5 mg/ml in PBS) were added to each well and the plate 
was incubated for further 4 h (37 C). The resulting formazan was dissolved in 150 µL of 0.04 N HCl/2-
propanol and read at 550 nm. All determinations were carried out in triplicate. 
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